We value your privacy

This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.

Powered by

Epclusa

ACNU Feasibility

View full report
GoodEpclusa is an oral tablet for Hepatitis C with moderate side effects, significant drug interactions, and special population cautions. It requires strict 12-week adherence, regular liver monitoring, and has low misuse risk but moderate dosing and adherence challenges.

ACNU Feasibility Scorecard

Chart with 11 data points.
Epclusa
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 8.
End of interactive chart.